000			04267nam a22003975i 4500
710	2		_aSpringerLink (Online service) _0Local _9106996
988			_aSpringer_Medicine_2015
999			_c82285 _d82285 _x1
001			82285
003			ES-MaUEC
005			20230207040404.0
007			cr nn 008mamaa
008			150613s2015 gw | s |||| 0|eng d
020			_a9783319141510
024	7		_a10.1007/978-3-319-14151-0 _2doi
040			_aES-MaUEC
050		4	_aRM666.E548 _b2015 EB
245	1	0	_aPARP Inhibitors for Cancer Therapy _cedited by Nicola J. Curtin, Ricky A. Sharma.
260			_aCham _bSpringer International Publishing _bImprint: Humana Press _c2015.
300			_a1 recurso en línea (XIX, 591 páginas) _b108 ilustraciones, 85 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCancer Drug Discovery and Development _x2196-9906 _v83
505	0		_aHistory of the discovery of poly (ADP-ribose) -- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members -- The role of PARPs in DNA Strand Break Repair -- TIPs: Tankyrase Interacting Proteins -- PARP and Carcinogenesis -- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity -- Overview of PARP Inhibitor Design and Optimization -- Structure Based Design of PARP Inhibitors -- Preclinical chemosensitization by PARP inhibitors -- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents -- Radiosensitisation by poly(ADP-ribose) polymerase inhibition -- The vasoactivity of PARP inhibitors -- Synthetic lethality with Homologous Recombination Repair defects -- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality -- Other determinants of sensitivity -- Synthetic sickness with molecularly targeted agents against the EGFR pathway -- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition -- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations -- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration -- Introduction to PARPi clinical trials and future directions -- Clinical trials investigating PARP inhibitors as single agents -- Clinical trials of PARP inhibitors with chemotherapy -- Combination of PARP inhibitors with clinical radiotherapy -- Biomarkers for PARP Inhibitors.
520	3		_aPARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARPâ€{u0BEC}y ADP ribose polymeraseâ€{u9BA0}cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors. PARP inhibitorsâ€{u0052}Piâ€{u1CA5} a group of pharmacological inhibitors that are particularly good targets for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA-damaging agents used to treat cancer. Researchers have learned a great deal about the biology of PARP and how tumor-specific defects in DNA repair can be exploited by PARPi. The “synthetic lethalityâ€{u0BE6} PARPi is an exciting concept for cancer therapy, and has led to heightened activity in this area.
650		7	_aResistencia a los medicamentos _2embne _9146972
650		7	_aBiología molecular _2embne _9139103
650	2	7	_aBiología molecular _2embne _9139103
700	1		_aCurtin, Nicola J. _eeditor literario _0Local _995114
700	1		_aSharma, Ricky A _eeditor literario _995115 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-14151-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12909257 _b10-10-17 _c10-02-16
942			_2lcc _cLE
945			_aRM666.E548 P377 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11576935 _z06-04-17
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0